Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA cross-linking via alkylation by cyclophosphamide refers to the formation of covalent bonds between two strands of DNA, predominantly at guanine N-7 positions, caused by the active cyclophosphamide metabolite phosphoramide mustard. This leads to inter- and intrastrand cross-links, blocking DNA replication and transcription, and ultimately resulting in cell cycle arrest and apoptosis. This molecular lesion is the primary mediator of cyclophosphamide's cytotoxic effects against cancer and certain immune cells. DNA cross-linking is not a protein or receptor, but a chemical modification of DNA, and represents a cytotoxic damage mechanism rather than a discrete druggable "target"[1][2][3][4][5][6][7][8].
Formation of covalent bonds (alkylation) with DNA at the N-7 position of guanine, leading to DNA cross-links that block replication and transcription, resulting in apoptosis[1][2][3][4][5][6].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA cross-link (specifically, phosphoramide mustard-induced DNA cross-link).